[Results of treatment for acromegaly with long-acting bromocriptine (Parlodel LAR)]. 1993

G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
Katedra i Klinika Endokrynologii AM, Wrocławiu.

Long-acting bromocriptine (Parlodel LAR) was used for treatment of 25 patients with acromegaly during the period of 3 to 24 months. Even after the first intramuscular injection of 50 milligrams of the drug a decrease in growth hormone (GH) concentration by at least 50% of the initial values was observed in 28% of patients and an improvement in a sense of well-being in 44%. After 6 months of administration of 100 mg of Parlodel LAR at intervals of 28 days a decrease in GH level by at least 50% was observed in a larger percentage of patients (36.8%), and in 10.5% of them there was a fall of GH concentration to below 10 microU/ml. Side effects, like nausea, vomiting and orthostatic hypotony, appeared within several hours after the injection of Parlodel and lasted in most cases up to 24 hours. After consecutive injections of the drug the side effects were of lesser intensity or completely disappeared. The results obtained allow to conclude that Parlodel LAR is an effective drug in some cases of acromegaly. In most patients the therapeutic effect can be seen after the first injection, but in some cases it appears only after several months of treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin

Related Publications

G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
January 1992, Endokrynologia Polska,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
May 1993, Fertility and sterility,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
September 1977, Vnitrni lekarstvi,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
May 1978, Ugeskrift for laeger,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
December 1991, Journal of endocrinological investigation,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
January 1996, Journal of endocrinological investigation,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
January 1992, Endokrynologia Polska,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
February 1992, Fertility and sterility,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
January 1978, Acta endocrinologica. Supplementum,
G Bednarek-Tupikowska, and A Bohdanowicz-Pawlak, and M Bolanowski, and J Jedrzejak, and A Milewicz
January 1995, Annales d'endocrinologie,
Copied contents to your clipboard!